期刊文献+

中国制药企业在美国市场中应对授权仿制药竞争的策略研究 被引量:6

Research on Strategy of China Pharmaceutical Companies Coping with Competition of Authorized Generics in American Drug Market
原文传递
导出
摘要 目的通过对美国授权仿制药战略原理、特点以及影响进行研究,为中国学者探讨授权仿制药战略以及中国制药企业在美国市场面临授权仿制药竞争时提供借鉴。方法通过案例分析和政策解析,总结品牌药厂商在美国市场中使用授权仿制药策略的特点。结论与结果成功的授权仿制药战略能够使品牌药厂商的产品在专利到期后仍能后维持较大的市场份额。中国制药企业需要根据自身的情况在美国市场选择不同的授权仿制药策略。 ObjectiveTo study the principle, feature and impact of the authorized generics strategy in American drug market, thus to provide some references for Chinese scholars who research the authorized generics strategy and for China pharmaceutical companies that would face competition in American pharmaceutical market. Methods By case study and policies analysis, the ways how the brand-name companies used the authorized generics in American drug market were summarized. Results AND Conclusion Successful authorized generics strategy can maintain a large market share of the brand-name companies products. In American drug market, there are some particularities about the authorize generics strategy due to the features of American drug policies and regulations. China pharmaceutical companies should implement different authorized generics strategy according to their own conditions in American drug market at present.
出处 《中国药学杂志》 CAS CSCD 北大核心 2013年第14期1217-1222,共6页 Chinese Pharmaceutical Journal
基金 国家自然科学基金资助项目(71003037) 教育部人文社会科学研究一般项目(11YJA630224)
关键词 授权仿制药 独立仿制药 品牌药 专利 战略 authorized generics, independent generics, brand-name drug, patent strategy
  • 相关文献

参考文献21

  • 1BARRY P. As Lipitor Goes Off Patent, What Will Happen to Price of Your Prescription [ EB/OL]. (2011-12-11) http:/! www. aarp. org/health/drugs-supplements/info-11-2011/lipitor- goes-off-patent, html. 被引量:1
  • 2STATON T. Ranbaxy pulls ahead of Pfizer in Lipitor race [ EB/ OL]. (2012-08-12) http ://www. fiercepharma, com/story/ranb- axy -pulls -ahead -pfizer-lipitor-race/2012434 -09. 被引量:1
  • 3Big Pharma' s 2009-2013 Patent Cliff[ EB/OL ]. ( 2011-11-22 ) http://aladinre, wrlc. org/bitstream/1961/9359/1/Jardines,% 20 Ben% 20-% 20Spring% 2010% 20 (P). pdf. 被引量:1
  • 4FDA. Letter to Stuart A. Williams (Mylan Pharmaceuticals) and James N. Czaban (Heller Ehrman), RE: Docket Nos [ EB/ OL]. at2 (2011-12-8). http://www, fda. gov/ohrms/DOCK- ETS/dailys/04/julyO4/070704/04p-0075-pdn0001. pdf. 被引量:1
  • 5GLASS G. Authorized Generics[ J]. Nature Reviews Drug Discov- ery, 2005,4(12) :954. 被引量:1
  • 6HOLLIS A. The Anti-competitive Effects of Brand-Controlled " Pseudo-Generics" in the Canadian Pharmaceutical Market [ J ]. Canadian Public Policy/Analyse de Politiques ,2003,29 (1) :30. 被引量:1
  • 7HESS J. Battle for the market: Branded Drug Companies" Secret Weapons Generic Drug Makers Must Know [ J ]. J Generic Medi-tines,2005,3 ( 8 ) :20-29. 被引量:1
  • 8FTC. "Branded Generics" as a Strategy to Limit Cannibalizatio~ of Pharmaceutical Markets [ EB/OL ]. 2005,5 : 10-11. ( 2011-12-3 ) http ://www. ftc. gov/be/heahhcare/wp/12 _ Reiffen BrandedGenericsAsAStrategy. pdf. 被引量:1
  • 9GREENSTONE LIMITED. Generic Pharmaceuticals: Adding Value and Access[J]. Drug Topics, 2006,150(2) :1. 被引量:1
  • 10DING J X, BAI G L, WANG Y W, et aL The system of america first generic drug data protection and Its inspiration to the drug accessibility in China [ J ]. 中国药学杂志,2012,47(24):2052. 被引量:1

同被引文献86

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部